Compare Stocks: VRDN, ABVX, PRAX, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$119.46 +0.4%	$126.18	$69.81 ▼ $148.83	$10.42B	0.96	1.43 million shs	985,408 shs
KYMR Kymera Therapeutics	$115.43 -0.9%	$114.36	$42.71 ▼ $130.05	$9.60B	1.96	733,464 shs	767,422 shs
PRAX Praxis Precision Medicines	$345.30 -2.0%	$339.30	$37.24 ▼ $392.70	$9.64B	2.76	460,180 shs	379,846 shs
VRDN Viridian Therapeutics	$22.73 -1.9%	$21.29	$13.18 ▼ $34.29	$2.58B	0.97	2.12 million shs	1.58 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+3.62%	+4.65%	-9.15%	+21.34%	+32.17%
KYMR Kymera Therapeutics	-0.78%	-2.17%	+8.32%	+48.88%	+169.23%
PRAX Praxis Precision Medicines	+0.19%	-0.27%	-2.30%	+46.46%	+764.98%
VRDN Viridian Therapeutics	+1.09%	+0.61%	-1.78%	+46.92%	+16.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$119.46 +0.4%	$126.18	$69.81 ▼ $148.83	$10.42B	0.96	1.43 million shs	985,408 shs
KYMR Kymera Therapeutics	$115.43 -0.9%	$114.36	$42.71 ▼ $130.05	$9.60B	1.96	733,464 shs	767,422 shs
PRAX Praxis Precision Medicines	$345.30 -2.0%	$339.30	$37.24 ▼ $392.70	$9.64B	2.76	460,180 shs	379,846 shs
VRDN Viridian Therapeutics	$22.73 -1.9%	$21.29	$13.18 ▼ $34.29	$2.58B	0.97	2.12 million shs	1.58 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+3.62%	+4.65%	-9.15%	+21.34%	+32.17%
KYMR Kymera Therapeutics	-0.78%	-2.17%	+8.32%	+48.88%	+169.23%
PRAX Praxis Precision Medicines	+0.19%	-0.27%	-2.30%	+46.46%	+764.98%
VRDN Viridian Therapeutics	+1.09%	+0.61%	-1.78%	+46.92%	+16.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.80	Moderate Buy	$156.50	33.48% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$128.70	10.93% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$585.95	67.59% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.54	66.98% Upside

Current Analyst Ratings Breakdown

Latest VRDN, ABVX, PRAX, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00
8/7/2026	PRAX Praxis Precision Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$323.00 ➝ $362.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
KYMR Kymera Therapeutics	$105M	91.88	N/A	N/A	$19.42 per share	5.97
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	$34.85 per share	N/A
VRDN Viridian Therapeutics	$71.13M	36.76	N/A	N/A	$6.18 per share	3.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest VRDN, ABVX, PRAX, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9585	N/A	N/A	N/A	$0.78 million	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
KYMR Kymera Therapeutics	N/A	10.34	10.34
PRAX Praxis Precision Medicines	N/A	15.73	15.73
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
KYMR Kymera Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
KYMR Kymera Therapeutics	15.98%
PRAX Praxis Precision Medicines	3.00%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.25 million	N/A	Not Optionable
KYMR Kymera Therapeutics	170	83.15 million	69.86 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

VRDN, ABVX, PRAX, and KYMR Headlines

Recent News About These Companies

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8 at 9:00 AM | globenewswire.com

Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

September 8 at 3:37 AM | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5, 2026 | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3, 2026 | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2, 2026 | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31, 2026 | marketbeat.com

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25, 2026 | marketbeat.com

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19, 2026 | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, ABVX, PRAX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

$119.46 +0.51 (+0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$120.88 +1.42 (+1.19%)

As of 06:06 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Kymera Therapeutics NASDAQ:KYMR

$115.43 -1.04 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$115.48 +0.04 (+0.04%)

As of 05:20 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$345.30 -7.18 (-2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$343.62 -1.68 (-0.49%)

As of 06:08 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Viridian Therapeutics NASDAQ:VRDN

$22.73 -0.44 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$22.74 +0.01 (+0.04%)

As of 06:03 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRDN, ABVX, PRAX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRDN, ABVX, PRAX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRDN, ABVX, PRAX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, ABVX, PRAX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRDN, ABVX, PRAX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRDN, ABVX, PRAX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRDN, ABVX, PRAX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, ABVX, PRAX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools